Aspirin Use for the Primary Prevention of Cardiovascular Diseases in Type 2 Diabetic Patients
Keywords:
aspirin; primary prevention; cardiovascular disease; type II diabetesAbstract
Background and Objective: To evaluate the efficacy and safety of aspirin use for primary prevention of cardiovascular disease in type 2 diabetic patients. Methods: A retrospective cohort study was performed in this study. Data were followed for 8 years in patients diagnosed with type 2 diabetes since 2009. Results: There were 305 patients (154 patients in aspirin group and 151 patients in non-aspirin group) enrolled in this study. The mean age of each group was 68.40 years. The percentage of cardiovascular events in aspirin group was not significantly different from non-aspirin group (79.90% and 88.10% respectively; p>0.05). There was no statistically significant difference of major gastrointestinal bleeding between the groups. Conclusion: Type 2 diabetic patients who received aspirin for primary prevention occurring cardiovascular events and major gastrointestinal bleeding were not significantly different from those who did not.References
1. American Diabetes Association. Standards of medical care in diabetes 2009. Diabetes care 2009; 32: S13-61.
2. American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes care 2010; 33: S11-61.
3. American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes care 2011; 34: S11-61.
4. American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes care 2012; 35: S11-63.
5. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes care 2013; 36: S11-66.
6. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes care 2014; 36: S14-80.
7. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes care 2015; 36: S1-93.
8. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes care 2016; 36: S1-106.
9. Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Int Med 2016; 164(12): 836-45.
10. Health Systems Research Institute. Thai people spend more than one hundred thirty billion in 2010. Faster than economic and health costs [Internet]. 2011 [cited Feb 16, 2017]. Available from: https://www.hsri.or.th/researcher/media/news/detail/4042.
11. World Health Organization. Cardiovascular diseases [Internet]. 2011 [cited Feb 16, 2017]. Available from:http:// www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
12. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999; 22: 1887-98.
13. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55(25): 2878-86.
14. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100: ii1-67.
15. U.S.FDA. Use of aspirin for primary prevention of heart attack and stroke [Internet]. 2016 [cited Sep 20,2018]. Available from: https://www.fda.gov/drugs/resourcesforyou/ consumers/ucm390574.htm.
16. The ASCEND study collaborative group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379: 1529-39.
17. The Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
2. American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes care 2010; 33: S11-61.
3. American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes care 2011; 34: S11-61.
4. American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes care 2012; 35: S11-63.
5. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes care 2013; 36: S11-66.
6. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes care 2014; 36: S14-80.
7. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes care 2015; 36: S1-93.
8. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes care 2016; 36: S1-106.
9. Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Int Med 2016; 164(12): 836-45.
10. Health Systems Research Institute. Thai people spend more than one hundred thirty billion in 2010. Faster than economic and health costs [Internet]. 2011 [cited Feb 16, 2017]. Available from: https://www.hsri.or.th/researcher/media/news/detail/4042.
11. World Health Organization. Cardiovascular diseases [Internet]. 2011 [cited Feb 16, 2017]. Available from:http:// www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
12. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999; 22: 1887-98.
13. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55(25): 2878-86.
14. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100: ii1-67.
15. U.S.FDA. Use of aspirin for primary prevention of heart attack and stroke [Internet]. 2016 [cited Sep 20,2018]. Available from: https://www.fda.gov/drugs/resourcesforyou/ consumers/ucm390574.htm.
16. The ASCEND study collaborative group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379: 1529-39.
17. The Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
Downloads
Published
2019-04-01
How to Cite
1.
Chuemongkon W, Boonruang K, Tumpoo K. Aspirin Use for the Primary Prevention of Cardiovascular Diseases in Type 2 Diabetic Patients. SRIMEDJ [Internet]. 2019 Apr. 1 [cited 2024 Nov. 25];34(2):184-9. Available from: https://li01.tci-thaijo.org/index.php/SRIMEDJ/article/view/181358
Issue
Section
Original Articles
